ArticleJournal of hepatocellular carcinoma2025
Real-World Comparison of Lenvatinib and Sorafenib as First-Line Treatments for Hepatocellular Carcinoma: A Multicenter Study.
Mira Kang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.